Highlights Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
5.2 ^USD	+0.58%		-7.64%	-48.67%

May. 30	Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating	MT
May. 14	Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	CI
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
Editas Medicine and Vertex Pharmaceuticals Enter into Non-Exclusive License Agreement for Cas9	Dec. 13	CI
Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology Annual Meeting And In A Company-Sponsored Webinar	Dec. 11	CI
Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar	Nov. 02	CI
Editas Medicine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Editas Medicine, Inc. and Azzur Cleanrooms on Demand, Azzur Group Company, Expand their Multi-Year Contract to Support Scaling of EDIT-301	23-07-27	CI
Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial	23-06-09	CI
Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress	23-05-11	CI
Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director	23-04-13	GL
Editas Medicine's Q4 Net Loss Widens, Revenue Falls	23-02-22	MT
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-22	CI
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-22	CI
Shoreline Biosciences, Inc. completed the acquisition of Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.	23-01-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Highlights

Filters